• OPKO Health unit OPKO Biologics dosed the first participant in a first-in-human Phase 1/2a trial of OPK-8801001 for acromegaly.
• The trial will assess safety, tolerability and pharmacological activity of the investigational long-acting growth hormone receptor antagonist.
• OPK-8801001 targets once-weekly administration; preclinical studies showed sustained, dose-dependent suppression of insulin-like growth factor-1, a marker of acromegaly activity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270800PRIMZONEFULLFEED9853690) on October 27, 2026, and is solely responsible for the information contained therein.